Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02154529 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT02154529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02154529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2014
Completion date
September 13, 2015
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer, metastatic malignant neoplasm to brain